PIWIL1

Caris Life Sciences to Showcase Extensive Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at ASCO 2024

Retrieved on: 
Martedì, Maggio 14, 2024
SCLC, Lung, Patient, Prognosis, Doctor of Philosophy, Immunotherapy, POA, PIWIL1, Diagnosis, Neoplasm, Endometrial cancer, TP53, Carcinoma, Breast cancer, NSCLC, Prostate, MBA, MD, Prostate cancer, Abstract, Research, Cancer, Biomarker, ASCO, CRC, Data analysis, Lung cancer, Medicine, ESR1, RNA, Society, Hepatocellular carcinoma, Genotype, Breast, NCI, HSD3B1, Annual general meeting, Medical imaging

IRVING, Texas, May 14, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting May 31 to June 4, 2024 (Booth #28001). The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • Through extensive sequencing and data analysis efforts, we're unlocking new avenues for tailored therapies to revolutionize cancer treatment."
  • (Abstract Number: 8088)
    Poster and abstract summaries highlighting the Caris research presented at ASCO 2024 will be available onsite at Caris' Booth 28001.
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Research, HLA, Nivolumab, Sale, Skin, PRISM, PR, SME, Commercial, PIWIL1, Neoplasm, Research and development, CTA, Melanoma, BMY, HBV, Progression-free survival, Treatment, GMP, Cancer, Bristol Myers Squibb, Convertible, APC, Security (finance), Congress, Circulating tumor DNA, DNA, Immune system, Lung cancer, Total, ESMO, Conference, Safety, Ovary, RECIST, Infection, Oncology, IND, Mum, Conference call, PFS, Note, Annual report, Pro forma, PRAME, Event, Patient, TCR, HIV, Pharmaceutical industry

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Retrieved on: 
Venerdì, Gennaio 5, 2024
Conference, ESMO, APC, PRAME, Treatment, Lung cancer, Immune system, IND, TCR, HBV, CMC, HLA, Melanoma, Nivolumab, Research, PIWIL1, Cancer, Standard of care, ImmTAC, Neoplasm, HIV, Ovary, PST, Webcast, Patient, Infection, Endometrium, CTA, Skin, Pharmaceutical industry

The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.

Key Points: 
  • The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
  • The Company has updated its corporate presentation to reflect these business and strategic updates.
  • Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
  • The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Novembre 7, 2023
Research, European Organisation for Research and Treatment of Cancer, Treatment, Ipilimumab, Record, Melanoma, Viral load, OS, Neoplasm, PIWIL1, BRAF, Sale, ESMO, EORTC, HIV, Circulating tumor DNA, World Games, The New England Journal of Medicine, Cancer, Patient, DNA, Nivolumab, Congress, CTA, MAD, Insming, Oncology, RFS, PRAME, Nivolumab/relatlimab, TCR International, European Society of Gynaecological Oncology, IND, SVP, TCR, Gastrointestinal cancer, European Society for Medical Oncology, Observation, Senior, Infection, Book, James A. Schlipmann Melanoma Cancer Foundation, HBV, Pharmaceutical industry, Cryptocurrency, Medical imaging, USD, IMC, Immunocore

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 10, 2023
Gastrointestinal cancer, PRAME, Patient, Ipilimumab, Commercial, IMC, Uveal melanoma, Infection, Research, MAD, Conference, Book, Safety, Abstract, DNA, AACR, HLA, Cancer, Record, BRAF, Medicine, Immunotherapy, TCR, CROI, James A. Schlipmann Melanoma Cancer Foundation, PIWIL1, Neoplasm, ImmTAC, Arm, HIV, OS, CTA, Fungal infection, Mum, Sale, ASCO, CTAS, American Society of Clinical Oncology, Melanoma, Annual general meeting, IND Queens Boulevard Line, Viral load, Society, Pharmaceutical industry, Cryptocurrency, Communications satellite, Immunocore, IL6

During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.

Key Points: 
  • During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
  • In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK.
  • The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND / CTA in the fourth quarter of 2023.

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

Retrieved on: 
Lunedì, Gennaio 9, 2023
IND, PRAME, PIWIL1, NSCLC, ImmTAC, Circulating tumor DNA, HBV, Neoplasm, GI, RECIST, Immunotherapy, Autoimmunity, HIV, DNA, Pancreatic cancer, Infection, Conference, ESMO, Webcast, TCR, Patient, CD3, Single, Cancer, HLE, Endometrial cancer, HLA-A24, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Q4, IMC, Immunocore, EU

In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.

Key Points: 
  • In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
  • The IMC-F106C-101 trial is adaptive and enables combinations with standards-of-care including checkpoint inhibitors, chemotherapy, and tebentafusp.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023.
  • The Company plans to report data from the Single Ascending Dose portion of the Phase 1 HIV trial in 2023.